Novartis AG annual gross margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG Gross Margin Growth & History (NVS)
Novartis AG's gross margin was 78.81% for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 78.81% | +1.51 pp |
| 2024 | 2024-12-31 | 77.30% | +2.06 pp |
| 2023 | 2023-12-31 | 75.24% | −0.29 pp |
| 2022 | 2022-12-31 | 75.53% | +0.17 pp |
| 2021 | 2021-12-31 | 75.36% | +3.89 pp |
| 2020 | 2020-12-31 | 71.47% | −0.64 pp |
| 2019 | 2019-12-31 | 72.11% | +1.65 pp |
| 2018 | 2018-12-31 | 70.46% | +0.21 pp |
| 2017 | 2017-12-31 | 70.25% | +4.46 pp |
| 2016 | 2016-12-31 | 65.78% | — |
Novartis AG quarterly gross margin
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 75.19% | −6.74 pp |
| Q1 2026 | 2026-03-31 | 74.42% | — |
| Q4 2025 | 2025-12-31 | 73.95% | — |
| Q3 2025 | 2025-09-30 | 75.35% | — |
| Q2 2025 | 2025-06-30 | 81.93% | +4.41 pp |
| Q2 2024 | 2024-06-30 | 77.52% | +4.05 pp |
| Q2 2023 | 2023-06-30 | 73.47% | +0.44 pp |
| Q2 2022 | 2022-06-30 | 73.03% | +0.63 pp |
| Q2 2021 | 2021-06-30 | 72.40% | +0.19 pp |
| Q2 2020 | 2020-06-30 | 72.20% | −1.05 pp |
| Q2 2019 | 2019-06-30 | 73.26% | +1.99 pp |
| Q2 2018 | 2018-06-30 | 71.27% | +3.99 pp |
| Q2 2017 | 2017-06-30 | 67.28% | — |
Novartis AG gross margin trends
Over the last five fiscal years, Novartis AG's gross margin increased from 71.47% to 78.81%, a change of +7.34 percentage points. The latest reported quarter, Q2 2026, shows 75.19%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
